تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Amgen Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $236.4B | |
|---|---|---|
| Revenue (ttm) | 38.1B | |
| Net income (ttm) | 8.7B | |
| EPS (ttm) | $16.1 | |
| Shares out | 540.6M | |
| P/E (trailing) | 28.1x | |
| P/E (forward) | 18.2x | |
| Dividend | $10.1 (2.23%) | |
| Volume | 2,016,147 | |
| Beta | 0.41 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B | +9.1% |
| Gross profit | $19.53B | $19.92B | $19.74B | $20.57B | $26.01B | +7.4% |
| Operating income | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B | +4.4% |
| Net income | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B | +7.0% |
| EPS (diluted) | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 | +8.5% |
| EBITDA | $11.30B | $12.17B | $7.90B | $13.36B | $16.90B | +10.6% |
| R&D | $6.32B | $4.43B | $4.78B | $5.96B | $6.97B | +2.5% |
| SG&A | $5.37B | $5.41B | $6.18B | $7.10B | $7.05B | +7.1% |
Recent company headlines from major financial publishers.
Moderate growth and continued cash backing support the central valuation outlook. Evidence should emerge by FY2027 through annual revenue and adjusted EPS delivery.
Stronger revenue, earnings, and cash would extend growth duration without requiring a hyper-growth assumption. A low-end FY2027 earnings result would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.6% | $582 | $623 | $679 | $763 | $906 |
| 6.6% | $509 | $532 | $561 | $599 | $651 |
| 7.6% | $461 | $475 | $492 | $513 | $540 |
| 8.6% | $426 | $435 | $447 | $460 | $476 |
| 9.6% | $399 | $406 | $414 | $423 | $433 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
